Tumors of the Central Nervous System

In the 2021 edition of the CNS classification, MYCN amplification in spinal cord ventricular meningiomas is one of the molecular subtypes that correlates with poor prognosis.

Tumors and Neoplastic Lesions of Peripheral Nervous Tissues

The Consensus for Pathological Diagnosis of Peripheral Neuroblastic Tumors (2017) states that neuroblastomas are very heterogeneous tumors requiring genetic molecular testing for risk grouping, with (1) N-MYC amplicon multiplicity, (2) DNA ploidy, (3) 1p deletion (selective), and (4) 11q deletion (selective);

N-MYC ( MYCN) is routinely tested for use in NB (neuroblastoma), GNBi (ganglioneuroblastoma hybrid), and GNBn (ganglioneuroblastoma nodosa). Closely associated with infiltration, metastasis and poor prognosis of NB;

The Consensus specifically states that N-MYC probes from Abbott Vysis or Ambipin are recommended;

Gene overexpression will block cell differentiation, growth and proliferation, and MYCN gene amplification will lead to malignant proliferation of tumor cells.